Upgrade to SI Premium - Free Trial

Bristol-Myers Squibb (BMY) Reports Update on Phase 3 Opdivo (nivolumab) CheckMate -548 Trial

September 5, 2019 7:00 AM
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the Phase 3 CheckMate -548 trial evaluating the addition of Opdivo (nivolumab) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles